Molecular Markers in Treatment in Endometrial Cancer
کلید واژه ها
خلاصه
شرح
This is a prospective multicenter study to investigate the predictive value of molecular markers in endometrial cancer for lymph node metastasis, prognosis and treatment. For the previously studied tumor markers p53, p16, ER, PR and HER2neu, we want to investigate the expression in curettage material in relation to lymph node metastasis and prognosis among endometrial carcinoma patients. We also want to investigate the distribution of genetic alterations in fresh frozen tumor tissue in order to design prospective randomized treatment trials of metastatic endometrial cancer based on molecular profile. There will be a special emphasis on disturbances in the pathways influenced by new targeted therapy, such as inhibitors of Her2/NEU, EGFR, receptor tyrosine kinase, mTOR, PTEN and hormone receptor pathways.
تاریخ
| آخرین تأیید شده: | 11/30/2014 |
| اولین ارسال: | 12/25/2007 |
| ثبت نام تخمینی ارسال شد: | 01/21/2008 |
| اولین ارسال: | 01/22/2008 |
| آخرین بروزرسانی ارسال شده: | 12/21/2014 |
| آخرین به روزرسانی ارسال شده: | 12/22/2014 |
| تاریخ شروع مطالعه واقعی: | 03/31/2001 |
| تاریخ تخمین اولیه اولیه: | 11/30/2015 |
| تاریخ برآورد مطالعه: | 11/30/2017 |
شرایط یا بیماری
مداخله / درمان
Procedure: Consecutive numbers
فاز
گروههای بازو
| بازو | مداخله / درمان |
|---|---|
| Consecutive numbers Patients with endometrial cancer | Procedure: Consecutive numbers Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated. |
معیارهای صلاحیت
| جنسیت واجد شرایط مطالعه | Female |
| روش نمونه گیری | Non-Probability Sample |
| داوطلبان سالم را می پذیرد | آره |
| شاخص | Inclusion Criteria: - Women with endometrial carcinoma - Available endometrial biopsy - Informed consent Exclusion Criteria: - No informed consent |
نتیجه
اقدامات اولیه
1. Presence of lymph node metastases [At primary treatment]
اقدامات ثانویه
1. Recurrent disease, death from disease [5 years after primary treatment]
